Current page location

Genome Editing Research Center

Genome Editing Research Center
Objectives
  • Securing of technologies to respond to a national epidemic of an infectious disease
  • Development of new technologies to overcome super-bacteria
  • Securing of diagnostic and preventive technologies against viruses
  • Establishment of a network hub of technologies to deal with an infectious disease in Korea
Researcher
    Click on the name
researchers and research statement
name research fields
Choong-Min Ryu
/ Associate Director
  • Bacteria-bacteria communication, Bacteria-plant interactions, plant immunity
Jae Gu Pan
/ Principal Researcher
  • Microbial physiology and bioprocesses, multiple target antibiotics and antimicrobial enzyme
Won-Gon Kim
/ Principal Researcher
  • Discovery of natural antibacterials for super-bacteria treatment / synthetic biology of new antibacterials derived from antinomyces
Seung-Hwan Park
/ Principal Researcher
  • Functional genomics of Bacillus, NRPS lipopeptide antibiotics, Bacillus cell factory based on synthetic biology
Soo-Keun Choi
/ Principal Researcher
  • Bacillus genetics and Bacillus cell factory
Haeyoung Jeong
/ Principal Researcher
  • Analysis of microbial genome structure
Haryoung Poo
/ Principal Researcher
  • Research on cell immunity, vaccine adjuvant and immunity improvement technology, establishment of virus recombination antigen and antibody
Dae Gwin Jeong
/ Principal Researcher
  • Structure-based development of recombinant viral protein vaccines
  • Proteomic analysis of virus-host interaction
Doo-Jin Kim
/ Senior Researcher
  • Development of universal influenza vaccines
  • Mechanisms of action of immunomodulatory vaccine adjuvants
Sun-Woo Yoon
/ Senior Researcher
  • Pathogenesis and genetic characterization of influenza viruses
  • Development of influenza vaccine technologies using the reverse genetics system
Moo-Seung Lee
/ Senior Researcher
  • Molecular cell biology based-characterization of virulence factors in infected host
Hye Kwon Kim
/ Researcher
  • Viral infectious diseases in animals, Identification and characterization of novel viruses
Ji Hyung Kim
/ Researcher
  • Aquatic Animal Medicine(Virology)
Sung Kyun Park
/ Researcher
  • Immunology (B-cell biology, antibody), Molecular biology
research areas
  • Analysis and reengineering of bacterial genome for improved antibiotics production and Bacillus bacterial factory
  • Discovery of a multidrug resistance-modifying mechanism by small RNA
  • Discovery of natural antimicrobials and identification of antibiotic targets using a genomic library
  • Bacteria display of enzymes and vaccines
  • Bacteria-host interaction
  • Development of new vaccine technologies, including subunit, genetic, and live attenuated vaccines against influenza viruses
    • Several candidates of subunit vaccines have been developed via prokaryotic and eukaryotic protein expression systems, using the HA, M2, and NP antigens. We have succeeded in the design and mass production of novel vaccine candidates, and have currently evaluated their efficacies as vaccine candidates in animal models.
  • Development of new vaccine adjuvants using bacterial outer membrane vesicles (OMVs) and the investigation of its immunomodulatory mechanisms
    • As an efficacious vaccine adjuvant candidate, we have developed bacterial OMVs. Study of the immune mechanism of the adjuvant has revealed that it strongly induces both humoral and cellular immune responses by stimulating innate immune receptors such as TLRs. Recently we are also studying the antiviral effect and mechanisms of action of OMVs in vivo and in vitro. The efficacy of the OMV adjuvant has been evaluated in rodent as well as porcine models.
  • Basic research on pandemic influenza, including surveillance and genetic characterization
    • We have isolated influenza viruses from fecal samples of wild migratory birds and ducks in Korea. We have completely identified the positive isolates and have genetically and pathogenically characterized them (Namet al., J. Virol 2011). In addition, we have evaluated in vitro and in vivo activities of some candidates of antiviral agents.
Achievements
  • Probiotic Paenibacillus- Analysis of ita genome and interaction with plants
    • Understanding the characteristics of Paenibacillus strains and mechanism of plant growth promotion and resistance development
  • Discovery of NRP gene cluster from Paenibacillus polymyxa
    • Discovery of biosynthesis gene clusters of polymyxin, fusaricidin, and tridecaptin based on the genome information, their expression regulation, and generation of new antimicrobial metabolites
  • Discovery of novel antimicrobials with new mode-of-action
    • Development of new natural antimicrobials from antinomyces, fungi and plants
    • Investigation of multiple-target antibiotic mechanisms and discovery of new concept antibiotic targets
  • Discovery of new multiple drug resistance mechanisms based on small RNA
    • An activity monitoring system of the sRNA library and analysis of their functions in antibiotic resistance development
  • Roles of volatile organic compounds in bacteria communication
    • Systematic understanding of bacterial interaction by volatile organic compounds in antibiotic resistance development
  • Spore display system for enzymes and vaccines
    • Development of a new display system for enzymes and antigens on the surface of Bacillus spores
  • Bacteria acetylproteomes
    • Systematic identification and understanding of post-translationally acetylated proteins in bacteria
  • Transfer of technologies and know-how of refinement of canine influenza vaccine antigen
  • Development of candidate materials for universal vaccines based on HA and M2 antigens
  • Development of a new vaccine adjuvant ased on bacterial outer membrane vesicles (OMVs) and evaluation on the efficacy in small and large animal models
  • Investigation on the immunomodulatory and antiviral functions of OMVs
  • Isolation and characterization of influenza viruses from domestic wild birds, dogs, horses, and human patients.
Outstanding Papers
  • Jae Gu Pan (Corresponding) Appl Environ Microbiol. 79(24):7905-15.
    • Evolved cobalamin-independent methionine synthase (MetE) improves the acetate and thermal tolerance of Escherichia coli
  • Kwang-Sun Kim (Corresponding) BMC Microbiol. 13:266.
    • Escherichia coli YmdB regulates biofilm formation independently of its role as an RNase III modulator
  • Choong-Min Ryu (Corresponding) Nature Commun. 4:1809.
    • Interspecific bacterial sensing through airborne signals modulates locomotion and drug resistance
  • Won Gon Kim (Corresponding) PLoS One. 8(11):e78922.
    • Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action
  • Jae Gu Pan (Corresponding) Proteomics. 13(10):1726-36.
    • The acetylproteome of Gram-positive model bacterium Bacillus subtilis
  • Haryoung Poo (Co-corresponding) Angewandte Chem. 52:7684-9.
    • Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity
  • Haryoung Poo (Co-corresponding) Evid Based Compl Altern Med. 2013:635960.
    • A single-center, randomized double-blind placebo-controlled study evaluating the effects of poly-gamma-glutamate on human NK cell activity after an 8-week oral administration in healthy volunteers
  • Doo-Jin Kim (Co-first) J Invest Dermatol. 134(3):704-11.
    • Oral administration of poly-γ-glutamate ameliorates atopic dermatitis in Nc/Nga mice by suppressing Th2-biased immune response and production of IL-17A.
  • Sun-Woo Yoon (First) Curr Top Microbiol Immunol. 2014
    • Evolution and Ecology of Influenza A Viruses.